Overview

Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 29102 is administered cutaneously as single and multiple doses to healthy subjects. The study is divided into one single dose part, one part to compare pharmacokinetics between gender and one multiple dose part.
Phase:
Phase 1
Details
Lead Sponsor:
LEO Pharma